Absci (ABSI) vs IQVIA (IQV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Absci (ABSI) has outperformed IQVIA (IQV) over the past year, gaining 146.5% versus a gain of 28.5%. Over five years, IQV leads with a +3.7% price change compared with -13.3% for ABSI. IQVIA is the larger company by market cap ($42.19 billion vs $1.53 billion), about 27.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | IQV |
|---|---|---|
| Share price | $8.91 | $256.35 |
| Market cap | $1.53B | $42.19B |
| 1-day change | -3.36% | -0.68% |
| YTD return | +164.18% | +14.51% |
| 1-year return | +146.52% | +28.50% |
| 5-year return | -13.26% | +3.72% |
| P/E ratio (TTM) | — | 31.84 |
| Forward P/E | — | 17.78 |
| EPS (TTM) | $-0.79 | $8.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $16.31B |
| Revenue growth (YoY) | — | +5.87% |
| Net income (latest FY) | — | $1.36B |
| Gross margin | — | 33.29% |
| Operating margin | — | 13.38% |
| Net margin | — | 8.34% |
| 52-week high | $12.06 | $277.40 |
| 52-week low | $2.24 | $154.50 |
| Distance from 52-week high | -26.09% | -7.59% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +61.62% | +13.46% |
| Average volume | 3.45M | 1.45M |
| Shares outstanding | 171.61M | 164.60M |
| Employees | 140 | 94,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IQVIA is about 27.6 times larger than Absci by market value ($42.19B vs $1.53B).
- ABSI has outperformed IQV by 118.0 percentage points over the past year.
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
About IQVIA
IQV stock →IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 94,000 employees
ABSI vs IQV FAQ
Which is bigger, Absci or IQVIA?
IQVIA (IQV) is larger, with a market capitalization of $42.19B compared with $1.53B for Absci (ABSI).
Which stock has performed better over the past year, ABSI or IQV?
ABSI returned +146.52% over the past 12 months, compared with +28.50% for IQV (price return, excluding dividends). Past performance does not predict future results.
Are Absci and IQVIA in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.